Rapid Reversal of Carbapenemase-Producing Pseudomonas aeruginosa Epidemiology from blaVIM- to blaNDM-harbouring Isolates in a Greek Tertiary Care Hospital
- PMID: 39200062
- PMCID: PMC11350812
- DOI: 10.3390/antibiotics13080762
Rapid Reversal of Carbapenemase-Producing Pseudomonas aeruginosa Epidemiology from blaVIM- to blaNDM-harbouring Isolates in a Greek Tertiary Care Hospital
Abstract
Carbapenemase-producing Pseudomonas aeruginosa strains present a specific geographical distribution regarding the type of carbapenemase-encoding genes that they harbor. For more than twenty years, VIM-type enzymes were the only major carbapenemases that were detected among P. aeruginosa isolates in Greece until the emergence of NDM-1-encoding P. aeruginosa in early 2023. In the present study, we present the rapid reversal of the carbapenemase-producing P. aeruginosa epidemiology from blaVIM- to blaNDM-harbouring isolates that occurred in our hospital since then. Between January 2023 and February 2024, 139 isolates tested positive for carbapenemase production with the NG-Test CARBA 5 immunochromatographic assay. Eight isolates were processed with the Hybrispot antimicrobial resistance direct flow chip molecular assay, and the first NDM-producing isolate was further analyzed through whole genome sequencing and bioinformatics analysis. Multiple resistance genes were detected by molecular techniques in accordance with the extensively drug-resistant phenotype. The isolate that was subjected to whole-genome sequencing belonged to the P. aeruginosa high-risk clone ST308, and the blaNDM was located in the chromosome in accordance with previously reported data. During the study period, NDM-producing isolates were increasingly detected, and only five months after their emergence, they overcame VIM producers. Our results indicate the potential of this new clone to spread rapidly and predominate within healthcare institutions, further restricting the already limited treatment options.
Keywords: NDM; Pseudomonas aeruginosa; VIM; carbapenem resistance; carbapenemases; hospital infections.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Similar articles
-
VIM-1, VIM-2, and GES-5 Carbapenemases Among Pseudomonas aeruginosa Isolates at a Tertiary Hospital in Istanbul, Turkey.Microb Drug Resist. 2017 Apr;23(3):328-334. doi: 10.1089/mdr.2016.0012. Epub 2016 Jun 21. Microb Drug Resist. 2017. PMID: 27326514
-
Carbapenemase -producing Pseudomonas aeruginosa isolates from Turkey: first report of P. aeruginosa high-risk clones with VIM-5- and IMP-7-type carbapenemases in a tertiary hospital.Diagn Microbiol Infect Dis. 2021 Jan;99(1):115174. doi: 10.1016/j.diagmicrobio.2020.115174. Epub 2020 Aug 12. Diagn Microbiol Infect Dis. 2021. PMID: 32980808
-
Characterization of carbapenem-resistant Pseudomonas aeruginosa clinical isolates, carrying multiple genes coding for this antibiotic resistance.Ann Clin Microbiol Antimicrob. 2014 Sep 2;13:43. doi: 10.1186/s12941-014-0043-3. Ann Clin Microbiol Antimicrob. 2014. PMID: 25179208 Free PMC article.
-
Dissemination of Pseudomonas aeruginosa blaNDM-1-Positive ST308 Clone in Singapore.Microbiol Spectr. 2023 Jun 15;11(3):e0403322. doi: 10.1128/spectrum.04033-22. Epub 2023 Apr 12. Microbiol Spectr. 2023. PMID: 37042789 Free PMC article.
-
Fatal respiratory infection due to ST308 VIM-1-producing Pseudomonas aeruginosa in a lung transplant recipient: case report and review of the literature.BMC Infect Dis. 2020 Aug 26;20(1):635. doi: 10.1186/s12879-020-05338-3. BMC Infect Dis. 2020. PMID: 32847524 Free PMC article. Review.
Cited by
-
Changing Epidemiology of Carbapenemases Among Carbapenem-Resistant Enterobacterales in a Greek Tertiary Care Hospital in Athens, 2020 to 2023.Antibiotics (Basel). 2025 Feb 26;14(3):239. doi: 10.3390/antibiotics14030239. Antibiotics (Basel). 2025. PMID: 40149050 Free PMC article.
References
-
- WHO . WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. World Health Organization; Geneva, Switzerland: 2024.
-
- Antimicrobial Resistance Surveillance in Europe 2023–2021 Data. European Centre for Disease Prevention and Control and World Health Organization; Stockholm, Sweden: 2023.
-
- Horcajada J.P., Montero M., Oliver A., Sorlí L., Luque S., Gómez-Zorrilla S., Benito N., Grau S. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin. Microbiol. Rev. 2019;32:e00031-19. doi: 10.1128/CMR.00031-19. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous